• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $117 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-31 Mln

Galectin Therapeutics Inc. (GALT) Share Price

$1.96

As on 29-Feb-2024 16:00 EST

up-down-arrow $0.073.44%

  • Prev Close info

    $1.89

  • Day's Openinfo

    $1.94

  • Today's Highinfo

    $2.00

  • Today's Lowinfo

    $1.90

  • Today's Volumeinfo

    134,862

  • 52 Week rangeinfo

    $1.28 - 2.47

Please wait...

Galectin Therapeutics Inc. (GALT) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Galectin Therapeutics (GALT)
17.77 13.01 -2.25 -2.25 -4.43 -17.74 -20.04
S&P BSE Sensex*
2.08 2.78 10.09 25.07 14.52 15.51 13.32
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 29-Feb-2024  |  *As on 01-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Galectin Therapeutics (GALT)
46.90 -45.41 -7.59 -21.68 -16.62 2.68 240.89
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Galectin Therapeutics Inc. (GALT) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Galectin Therapeutics Inc. (GALT)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Galectin Therapeutics Inc. (GALT)

        President, CEO & Director

        Mr. Joel Lewis

        CFO, Treasurer & Corporate Secretary

        Mr. Jack W. Callicutt CPA

        Headquarters

        Norcross, GA

        FAQs for Galectin Therapeutics Inc. (GALT)

        The total asset value of Galectin Therapeutics Inc. (GALT) stood at $ 33 Mln as on 30-Sep-23

        The share price of Galectin Therapeutics Inc. (GALT) is $1.96 (NASDAQ) as of 29-Feb-2024 16:00 EST. Galectin Therapeutics Inc. (GALT) has given a return of -4.43% in the last 3 years.

        Galectin Therapeutics Inc. (GALT) has a market capitalisation of $ 117 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Galectin Therapeutics Inc. (GALT) is 207.70 times as on 29-Feb-2024, a 68.7% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Galectin Therapeutics Inc. (GALT) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Galectin Therapeutics Inc. (GALT) and enter the required number of quantities and click on buy to purchase the shares of Galectin Therapeutics Inc. (GALT).

        Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Address: 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071

        The CEO & director of Mr. Joel Lewis. is Galectin Therapeutics Inc. (GALT), and CFO & Sr. VP is Mr. Jack W. Callicutt CPA.

        The promoters of Galectin Therapeutics Inc. (GALT) have pledged 0% of the total equity as on Sep-23.

        Galectin Therapeutics Inc. (GALT) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        -1.2
        Dividend yield(%)
        0

        No, TTM profit after tax of Galectin Therapeutics Inc. (GALT) was $-31 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $116.89 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-31.40 Mln
        • Cash date-information $20.36 Mln
        • Total Debt info $61.22 Mln
        • Insider's Holding 31.32%
        • Liquidity liquidity High
        • 52 Week range week-range $1.28 - 2.47
        • Shares outstanding share-outstanding 61,848,700
        • 10 Years Aggregate:

          CFO: $-194.20 Mln

          EBITDA: $-191.78 Mln

          Net Profit: $-236.16 Mln

        About The Company

        • IPO Date 09-Sep-2002
        • President, CEO & Director Mr. Joel Lewis
        • CFO, Treasurer & Corporate Secretary Mr. Jack W. Callicutt CPA
        • Listing key-listing NASDAQ: GALT
        • Country United States
        • Headquarters headquarters Norcross, GA
        • Website website https://galectintherapeutics.com
        • Business

          Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a...  galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Address: 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071  Read more

        share-fund-plan-icon